Autolus Therapeutics vs Coherus Oncology
AUTL and CHRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and CHRS compare
Autolus Therapeutics is the larger company, worth 3.8 times as much as Coherus Oncology ($311M against $81.2M).
Autolus Therapeutics grew revenue faster over the last twelve months (169% versus 44.4% for Coherus Oncology).
Autolus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −186% compared with −253% at Coherus Oncology.
Coherus Oncology scores higher on the StockData Score (6 against 4 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | CHRS |
|---|---|---|
| Size and price | ||
| Market cap | $311M | $81.2M |
| Share price | $1.17 | $0.525 |
| Change, 1 year | −14.0% | −61.4% |
| Change, 5 years | −81.2% | −97.2% |
| Beta (5Y) | 1.84 | 1.37 |
| Employees | 754 | 147 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× | 1.5× (better) |
| P/B | 11.4× | 3.2× (better) |
| FCF yield | −57.9% | – |
| Fair value | – | $0.853 |
| Margin of safety | – | 38.4% |
| Growth | ||
| Revenue growth (TTM) | 169% (better) | 44.4% |
| Revenue growth, 5Y average | – | −38.4% |
| Net income growth (TTM) | – | −188% |
| EPS growth, 5Y average | – | −2.5% |
| Profitability | ||
| Gross margin | 35.8% | 69.8% (better) |
| Operating margin | −160% (better) | −276% |
| Net margin | −186% (better) | −253% |
| FCF margin | −131% | – |
| Return on equity | −175% (better) | −241% |
| Financial health | ||
| Interest coverage | −4.8× (better) | −15.5× |
| Current ratio | 3.72 (better) | 1.51 |
| Altman Z-score | −4.28 (better) | −14.06 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 49.7% | 45.5% |
| Held by insiders | 24.6% | 1.3% |
| Insider net buying, 12 months | −$15.7K | – |
| Short interest, % of float | – | 8.3% |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.